How do Repatha and Praluent work?
Repatha (evolocumab) and Praluent (alirocumab) are both PCSK9 inhibitors that lower LDL cholesterol by blocking the PCSK9 protein, which helps the liver remove more LDL from the blood. They are injected subcutaneously every 2–4 weeks and are used for high cholesterol, especially in patients with cardiovascular disease or familial hypercholesterolemia.[1][2]
Direct comparison of LDL reduction
Clinical trials show similar effectiveness in lowering LDL cholesterol. Repatha reduces LDL by 50–70% from baseline, while Praluent achieves 45–65%, depending on dose and patient population. In head-to-head data from the 2018 FOURIER and ODYSSEY trials, both drugs cut LDL to comparable levels (around 30–50 mg/dL) when added to statins. No large randomized trial directly proves one outperforms the other for LDL lowering.[3][4]
Impact on heart events and outcomes
Both reduce major cardiovascular events. Repatha (FOURIER trial, 27,564 patients) cut heart attacks, strokes, and cardiovascular death by 20% over statins alone. Praluent (ODYSSEY OUTCOMES, 18,924 patients) showed a 15% reduction in similar events. Differences are not statistically significant between drugs; patient baselines (e.g., recent acute coronary syndrome for Praluent) explain variations.[3][5]
| Metric | Repatha (FOURIER) | Praluent (ODYSSEY) |
|--------|-------------------|--------------------|
| LDL drop (mean) | 59% | 54% |
| CV event reduction | 20% | 15% |
| Trial size | 27,564 | 18,924 |
| Follow-up | 2.2 years | 2.8 years |
Which patients respond better to each?
Effectiveness is similar overall, but Repatha may edge out in homozygous familial hypercholesterolemia (up to 60% LDL drop vs. 40–50% for Praluent). Praluent has more flexible dosing options (75–150 mg). Real-world data shows 5–10% more patients reach LDL <70 mg/dL with Repatha, but adherence and side effects influence this.[6]
Side effects and tolerability
Both have low rates of injection-site reactions (5–7%), muscle pain, and flu-like symptoms. Repatha reports slightly fewer neurocognitive events (0.3% vs. 1% for Praluent), but serious risks like allergic reactions are rare and equal (<1%). No major safety differences.[1][2]
Cost and access factors
Annual list prices are close: Repatha ~$5,800/year, Praluent ~$5,700/year (U.S. 2023). Insurance coverage and copay cards often make them equivalent. Biosimilars are not yet available.[7]
Sources:
[1] Repatha.com (Amgen prescribing info)
[2] Praluent.com (Sanofi/Regeneron prescribing info)
[3] NEJM: FOURIER Trial (Repatha)
[4] NEJM: LAPLACE-2 (head-to-head LDL data)
[5] NEJM: ODYSSEY OUTCOMES (Praluent)
[6] Circulation: Real-world PCSK9 comparison
[7] Drugs.com pricing